4.7 Article

Cellular Reprogramming: Recent Advances in Modeling Neurological Diseases

期刊

JOURNAL OF NEUROSCIENCE
卷 31, 期 45, 页码 16070-16075

出版社

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.4218-11.2011

关键词

-

资金

  1. National Institutes of Health (NIH) [NS048271, HD069184, DPOD006395, NS066390, NS072381, NS052671, MH092931, NS073015]
  2. National Alliance for Research on Schizophrenia and Depression
  3. Maryland Stem Cell Research Fund (MSCRF)
  4. Johns Hopkins Brain Science Institute
  5. Deutsche Forschungsgemeinschaft [SFB TR3/D2]
  6. Bundesministerium fur Bildung und Forschung [01GNO813, 01GS0860, 01GN1008C, 01GN1009B, 0315799, 0315608A, 0316020]
  7. European Union [222943, 266753]
  8. BIO.NRW [w0911bt027a]
  9. Hertie Foundation
  10. California Institute for Regenerative Medicine (CIRM) [TR2-01814, RT2-02061]
  11. New York State grants [N08S-005-01 NYSTEM, N09-G277-01 NYSTEM]
  12. Ellison Medical Foundation

向作者/读者索取更多资源

The remarkable advances in cellular reprogramming have made it possible to generate a renewable source of human neurons from fibroblasts obtained from skin samples of neonates and adults. As a result, we can now investigate the etiology of neurological diseases at the cellular level using neuronal populations derived from patients, which harbor the same genetic mutations thought to be relevant to the risk for pathology. Therapeutic implications include the ability to establish new humanized disease models for understanding mechanisms, conduct high-throughput screening for novel biogenic compounds to reverse or prevent the disease phenotype, identify and engineer genetic rescue of causal mutations, and develop patient-specific cellular replacement strategies. Although this field offers enormous potential for understanding and treating neurological disease, there are still many issues that must be addressed before we can fully exploit this technology. Here we summarize several recent studies presented at a symposium at the 2011 annual meeting of the Society for Neuroscience, which highlight innovative approaches to cellular reprogramming and how this revolutionary technique is being refined to model neurodevelopmental and neurodegenerative diseases, such as autism spectrum disorders, schizophrenia, familial dysautonomia, and Alzheimer's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据